Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 1.00 |
| ▸ | MET | P08581 | 19/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2386002 | 0.90 | AXL (0.81) | AXLMETKCNH2 | |
| SCHEMBL2386019 | 0.89 | AXL (0.81) | AXLMETKCNH2 | |
| SCHEMBL3474312 | 0.89 | AXL (0.80) | AXLMETKCNH2 | |
| SCHEMBL2387699 | 0.89 | AXL (0.80) | AXLMETKCNH2 | |
| SCHEMBL2386633 | 0.89 | AXL (0.80) | AXLMETKCNH2 | |
| SCHEMBL2387603 | 0.88 | AXL (0.79) | AXLMETKCNH2 | |
| SCHEMBL2386893 | 0.88 | AXL (0.78) | AXLMETKCNH2 | |
| SCHEMBL2388186 | 0.88 | AXL (0.78) | AXLMETKCNH2 | |
| SCHEMBL12330311 | 0.88 | AXL (0.78) | AXLMETKCNH2 | |
| SCHEMBL2387071 | 0.87 | AXL (0.77) | AXLMETKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2215085-B1 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-09-07 | — | — | EP | claimed |
| EP-2215085-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-11 | — | — | EP | claimed |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | claimed |
| WO-2009053737-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | claimed |
| US-20190119649-A1 | METHODS FOR GENERATING AUGMENTED STEM CELL-DERIVED BETA CELLS AND USES THEREOF | HOWARD HUGHES MEDICAL INSTITUTE | 2019-04-25 | — | — | US | disclosed |
| US-20160177268-A1 | METHODS FOR GENERATING AUGMENTED STEM CELL-DERIVED BETA CELLS AND USES THEREOF | HOWARD HUGHES MEDICAL INSTITUTE | 2016-06-23 | — | — | US | disclosed |
| US-20160177268-A1 | METHODS FOR GENERATING AUGMENTED STEM CELL-DERIVED BETA CELLS AND USES THEREOF | HOWARD HUGHES MEDICAL INSTITUTE | 2016-06-23 | — | — | US | disclosed |
| US-8017611-B2 | Pyridine and pyrazine derivatives -083 | ASTRAZENECA AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-8017611-B2 | Pyridine and pyrazine derivatives -083 | ASTRAZENECA AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-8017611-B2 | Pyridine and pyrazine derivatives -083 | ASTRAZENECA AB (SE) | 2011-09-13 | — | — | US | disclosed |
| EP-2215085-B1 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-09-07 | — | — | EP | disclosed |
| EP-2215085-B1 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-09-07 | — | — | EP | disclosed |
| EP-2215085-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-11 | — | — | EP | disclosed |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| WO-2009053737-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009053737-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160177268-A1 | METHODS FOR GENERATING AUGMENTED STEM CELL-DERIVED BETA CELLS AND USES THEREOF | IAPP, AMY2A, PNLIP | AXL 4397/4885MET 1559/4885KCNH2 2808/4885 |
| US-20190119649-A1 | METHODS FOR GENERATING AUGMENTED STEM CELL-DERIVED BETA CELLS AND USES THEREOF | IAPP, AMY2A, PNLIP | AXL 4397/4885MET 1559/4885KCNH2 2808/4885 |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | MKI67, CCND3, CCND1 | AXL 2302/4885MET 2362/4885KCNH2 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.